Document text
Principal Investigator: Monica Gandhi
Organization: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Fiscal Year: 2023
Award: $242,250
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY/ ABSTRACT
At this point in the COVID-19 pandemic, with vaccine roll-out ongoing, one of the most urgent questions
facing people living with HIV (PLWH) and their providers is whether HIV modulates the immune response to
and subsequent effectiveness of the SARS-CoV-2 vaccines. Unfortunately, phase 3 trials for all three of the
U.S.-authorized vaccines did not report HIV specific data and/or did not include enough PLWH to examine the
impact of HIV infection on vaccine efficacy.
PLWH might plausibly experience a less durable SARS-CoV-2 specific neutralizing antibody (NAb) response
to a SARS-CoV-2 vaccine, as has been seen in response to vaccines for other infections. This lack of durable
NAb responses may be mediated by inflammatory state of HIV infection that persists despite adequate
suppressive antiretroviral therapy (ART), T cell exhaustion, and/or lower CD4/CD8 ratios. Our preliminary work
in the UCSF Long-term Impact of Infection with Novel Coronavirus (LIINC) COVID-19 recovery study has
demonstrated waning antibody responses but stable CD4+ and CD8+ T cell responses among HIV-negative
individuals recovering from natural SARS-CoV-2 infection. However, surrogate virus neutralization titers and
IgG concentrations were lower among PLWH compared to adults without HIV following mRNA vaccination,
raising concerns that PLWH might have a diminished humoral response to vaccination. Whether PLWH mount
less durable humoral and cell-mediated immune responses to COVID-19 vaccines than those without HIV is
largely unknown, including the mechanisms of these differences, although this information could inform clinical
strategies, including additional boosters or safety measures after vaccination.
This proposal will answer two vital questions about the response to vaccination among PLWH. Aim 1
will provide novel, urgently needed insights into how the SARS-CoV-2 neutralizing antibody response to a
cultured B.1.617.2 (delta) variant, IgG concentration, and antibody magnitude and durability could differ by HIV
status over time following mRNA-based SARS-CoV-2 vaccination, including following boosters. Aim 2 will
examine T cell memory responses and germinal center development generated by mRNA-based SARS-CoV-2
vaccination among PLWH compared to those without HIV out to a year following vaccination. Harnessing, the
research infrastructure of the UCSF CFAR, the LIINC study, and a large, aging population of PLWH
served by the Ward 86 clinic, this analysis will leverage an ongoing cohort to address whether PLWH mount
attenuated immune responses to COVID-19 vaccines. Such data will inform clinical and public health
responses, including the need for additional vaccine doses or safety strategies for PLWH during COVID-19.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><21+ years old><7S Gamma Globulin><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Adult><Adult Human><Age><Antibodies><Antibody Avidity><Antibody Response><Antibody titer measurement><Assay><Attenuated><Authorization><Authorization documentation><Automobile Driving><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><B.1.617.2><BLR1><BLR1 gene><Binding><Bioassay><Biologic Assays><Biological Assay><Booster Immunization><CD134><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 immunity><COVID-19 infection><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 vaccination><COVID-19 vaccine><COVID-19 virus><COVID-19 virus infection><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 immunity><COVID19 infection><COVID19 pandemic><COVID19 public health crisis><COVID19 vaccination><COVID19 vaccine><COVID19 virus><CV-19><CV19><CXCR-5><CXCR5><Catabolism><Cell Body><Cell Count><Cell Mediated Immunology><Cell Number><Cell-Mediated Immunity><Cells><Cellular Immunity><Clinic><Clinical><CoV emergence><CoV-2><CoV2><Data><Defect><Delta variant><Development><Dose><Dysfunction><Effectiveness><Failure><Functional disorder><Future><Germinal Center><HBV Vaccination><HIV><HIV Infections><HIV Seronegativities><HIV Seronegativity><HIV negative><HTLV-III Infections><HTLV-III Seronegativities><HTLV-III Seronegativity><HTLV-III-LAV Infections><Hep B vaccination><Hepatitis B Vaccination><Hepatitis B immunization><Hepatitis B injection><Hepatitis B series immunization><History><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><IDOase><IgG><Immune><Immune Markers><Immune response><Immunes><Immunity><Immunoglobulin G><Immunologic Markers><Immunological response><Immunomodulation><Impact evaluation><Impairment><Individual><Indoleamine 2,3-Dioxygenase><Infection><Inflammation><Inflammatory><Intercept><Investigation><Investigators><LAV-HTLV-III><LYT3><Linear Models><Lymphadenopathy-Associated Virus><MDR15><Measures><Mediating><Mediator><Memory B Cell><Memory B-Lymphocyte><Messenger RNA><Molecular Interaction><Nucleocapsid><OX40><PD 1><PD-1><PD1><Participant><Patients><Peptides><Permission><Persons><Physiopathology><Plasmablast><Population><Provider><Public Health><RNA immunization><RNA vaccination><Recording of previous events><Recovery><Reporting><Research Infrastructure><Research Personnel><Researchers><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.617.2><SARS-CoV-2 delta><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 immunity><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Secondary Immunization><Serology><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 immunity><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><South African><Structure of germinal center of lymph node><T cell response><T memory cell><T-Cell Activation><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><Time><Tryptophan 2,3 Dioxygenase><Vaccination><Vaccines><Variant><Variation><Virus><Virus-HIV><Work><Wuhan coronavirus><Yellow Fever><activate T cells><adulthood><aged population><ages><aging population><anti-retroviral therapy><anti-retroviral treatment><antibody titering><antiretroviral therapy><antiretroviral treatment><aspirate><attenuate><attenuates><authority><booster dose><booster shot><booster vaccination><booster vaccine><breakthrough infection><cell mediated immune response><cohort><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><corona virus emergence><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 immunity><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><deploy vaccines><developmental><distribute vaccines><draining lymph node><driving><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><exhaustion><experience><hCoV19><hepatitis B virus vaccination><histories><host response><immune modulation><immune regulation><immune system response><immune-based biomarkers><immunity against COVID-19><immunity against COVID19><immunity against SARS-CoV-2><immunity against Severe acute respiratory syndrome coronavirus 2><immunity against coronavirus disease 2019><immunity to COVID-19><immunity to COVID19><immunity to SARS-CoV-2><immunity to Severe acute respiratory syndrome coronavirus 2><immunity to coronavirus disease 2019><immunization against hepatitis B><immunologic reactivity control><immunological biomarkers><immunological markers><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><indexing><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inflammation marker><inflammatory marker><insight><mRNA><mRNA immunization><mRNA vaccination><memory T lymphocyte><nCoV><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><neutralizing antibody><neutralizing vaccine><new CoV><new corona virus><new coronavirus><novel><novel CoV><novel corona virus><novel coronavirus><pathophysiology><phase 3 trial><phase III trial><population aging><programmed cell death 1><programmed cell death protein 1><programmed death 1><public health relevance><receptor expression><recruit><regional lymph node><response><severe acute respiratory syndrome coronavirus 2 B.1.617.2><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><sex><sle2><systemic lupus erythematosus susceptibility 2><thymus derived lymphocyte><tryptamine 2,3 dioxygenase><vaccinate against COVID-19><vaccinate against COVID19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination against COVID-19><vaccination against COVID19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccination against hepatitis B><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine deployment><vaccine distribution><vaccine efficacy><vaccine for novel coronavirus><vaccine roll-out><vaccine rollout><vaccine study><vaccine trial><vaccine-induced immunity><vaccine-induced protection><ward>